Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease

The study covered 30 apparently healthy individuals and 38 patients with systemic scleroderma. The patients gave their consent to participate in the study in accordance with the World Medical Association Declaration of Helsinki in the current (2013) version (ACR/EULAR). The donors and patients had t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	O. I. Emelyanova, I. P. Gontar, O. A. Rusanova, I. A. Zborovskaya
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2021
Materias:	catalase systemic scleroderma antibodies magnetocontrollable sorbents diagnostics activity Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/f1881343747c4f9ba22e7ea149c9d291
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f1881343747c4f9ba22e7ea149c9d291
record_format	dspace
spelling	oai:doaj.org-article:f1881343747c4f9ba22e7ea149c9d2912021-11-18T08:03:50ZСatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease1563-06252313-741X10.15789/1563-0625-CAI-2098https://doaj.org/article/f1881343747c4f9ba22e7ea149c9d2912021-01-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/2098https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThe study covered 30 apparently healthy individuals and 38 patients with systemic scleroderma. The patients gave their consent to participate in the study in accordance with the World Medical Association Declaration of Helsinki in the current (2013) version (ACR/EULAR). The donors and patients had their blood tested for catalase antibodies with immunoenzyme assay and using magnetic sorbents upon hospital admission and before discharge. It was found that the patients with systemic scleroderma had a reduced oxidase activity of catalase as well as elevated catalase antibodies, compared with the controls. We revealed a statistically significant regularity that the concentration of catalase immunoglobulins is associated with activity and course of the disease. To assess the activity of systemic scleroderma we performed a complex evaluation of two parameters: enzymatic activity and catalase antibody levels. It was established that catalase autoantibodies are mostly revealed in patients with high-activity scleroderma, subacute and acute course of the disease, and when the lungs, skin, kidneys, joints and nervous system were involved, which was conclusively confirmed by a correlation analysis. It is especially important that catalase antibodies should be revealed at early stage of the disease development; they are of especial diagnostic importance, and their changes over time may form the basis for assessing efficiency of administered therapy. The changes in biochemical activity of catalase, elevated antibody titers provide additional criteria of diagnosis in systemic scleroderma. Monitoring of these parameters in hospital settings helps to evaluate the effectiveness of administered therapy and adjust its correction, which is confirmed by inclusion of such extracorporal techniques as plasma separation into the combined treatment schedules. Studying biochemical activity of catalase and formation of catalase antibodies expands our understanding of scleroderma development and opens new avenues for research.O. I. EmelyanovaI. P. GontarO. A. RusanovaI. A. ZborovskayaSPb RAACIarticlecatalasesystemic sclerodermaantibodiesmagnetocontrollable sorbentsdiagnosticsactivityImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 22, Iss 6, Pp 1179-1184 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	catalase systemic scleroderma antibodies magnetocontrollable sorbents diagnostics activity Immunologic diseases. Allergy RC581-607
spellingShingle	catalase systemic scleroderma antibodies magnetocontrollable sorbents diagnostics activity Immunologic diseases. Allergy RC581-607 O. I. Emelyanova I. P. Gontar O. A. Rusanova I. A. Zborovskaya Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease
description	The study covered 30 apparently healthy individuals and 38 patients with systemic scleroderma. The patients gave their consent to participate in the study in accordance with the World Medical Association Declaration of Helsinki in the current (2013) version (ACR/EULAR). The donors and patients had their blood tested for catalase antibodies with immunoenzyme assay and using magnetic sorbents upon hospital admission and before discharge. It was found that the patients with systemic scleroderma had a reduced oxidase activity of catalase as well as elevated catalase antibodies, compared with the controls. We revealed a statistically significant regularity that the concentration of catalase immunoglobulins is associated with activity and course of the disease. To assess the activity of systemic scleroderma we performed a complex evaluation of two parameters: enzymatic activity and catalase antibody levels. It was established that catalase autoantibodies are mostly revealed in patients with high-activity scleroderma, subacute and acute course of the disease, and when the lungs, skin, kidneys, joints and nervous system were involved, which was conclusively confirmed by a correlation analysis. It is especially important that catalase antibodies should be revealed at early stage of the disease development; they are of especial diagnostic importance, and their changes over time may form the basis for assessing efficiency of administered therapy. The changes in biochemical activity of catalase, elevated antibody titers provide additional criteria of diagnosis in systemic scleroderma. Monitoring of these parameters in hospital settings helps to evaluate the effectiveness of administered therapy and adjust its correction, which is confirmed by inclusion of such extracorporal techniques as plasma separation into the combined treatment schedules. Studying biochemical activity of catalase and formation of catalase antibodies expands our understanding of scleroderma development and opens new avenues for research.
format	article
author	O. I. Emelyanova I. P. Gontar O. A. Rusanova I. A. Zborovskaya
author_facet	O. I. Emelyanova I. P. Gontar O. A. Rusanova I. A. Zborovskaya
author_sort	O. I. Emelyanova
title	Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease
title_short	Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease
title_full	Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease
title_fullStr	Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease
title_full_unstemmed	Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease
title_sort	сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease
publisher	SPb RAACI
publishDate	2021
url	https://doaj.org/article/f1881343747c4f9ba22e7ea149c9d291
work_keys_str_mv	AT oiemelyanova satalaseantibodiesinpatientswithsystemicsclerodermaasadiagnosticandprognosticmarkerofthedisease AT ipgontar satalaseantibodiesinpatientswithsystemicsclerodermaasadiagnosticandprognosticmarkerofthedisease AT oarusanova satalaseantibodiesinpatientswithsystemicsclerodermaasadiagnosticandprognosticmarkerofthedisease AT iazborovskaya satalaseantibodiesinpatientswithsystemicsclerodermaasadiagnosticandprognosticmarkerofthedisease
_version_	1718422326904619008

Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease

Ejemplares similares